

CD



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/147,362	03/12/1999	DENIS MARIE BERNARD CHENEBAUX	P63163USO	1607
7590 06/30/2004				
JACOBSON PRICE HOLMAN & STERN 400 SEVENTH STREET NW WASHINGTON, DC 20004		EXAMINER PARKIN, JEFFREY S		
		ART UNIT PAPER NUMBER		
		1648		
DATE MAILED: 06/30/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/147,362			

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:


Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents

The communication filed on 19 February, 2004, is not fully responsive to the last Office action. Applicants are reminded of the sequence rules as set forth in § 2422.03 of the M.P.E.P. 37 CFR 1.821(d) requires the use of the assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences regardless of whether a given sequence is also embedded in the text of the description or claims of an application. This requirement is also intended to permit references, in both the description and claims, to sequences set forth in the "Sequence Listing" by the use of assigned sequence identifiers without repeating the sequence in the text of the description or claims. Sequence identifiers can also be used to discuss and/or claim parts or fragments of a properly presented sequence. For example, language such as "residues 14 to 243 of SEQ ID NO:23" is permissible and the fragment need not be separately presented in the "Sequence Listing." Applicants reference to "various regions" of various sequence identifiers is inappropriate. **Applicants should amend the claim language to recite a single sequence identifier and the corresponding region (i.e., Leu-Leu-Ser-Ser (amino acids 1-4 of SEQ ID NO.: 3)).** Applicant is given **ONE MONTH, or THIRTY DAYS**, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 C.F.R. § 1.821-1.825. Failure to comply with these requirements will result in **ABANDONMENT** of the application under 37 C.F.R. § 1.821(g). Direct the reply to the undersigned.

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If

attempts to reach the examiner are unsuccessful, the examiner's supervisors, Laurie Scheiner or James Housel, can be reached at (571) 272-0910 or (571) 272-0902, respectively.

Respectfully,

A handwritten signature in black ink, consisting of a large, stylized 'J' followed by a horizontal line extending to the right.

Jeffrey S. Parkin, Ph.D.  
Art Unit 1648

24 June, 2004